首页 > 按月查看>2023年第1期 >1-14. DOI:10.11798/j.issn.1007-1520.202322001
PDF HTML 导出
免疫调节剂治疗鼻部炎症性疾病专家共识(2023，深圳)
作者:
基金项目:

国家自然科学基金杰出青年基金(81725004)；国家自然科学基金(81870706，81670901，81873689，81873690，81870700，82071014，82171104，82171119，82171120，82101201，82260219，82071018)；上海市科委项目(20MC920200，19XD4010000)；上海市促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR4090)；上海申康医学发展中心临床科技创新项目(SHDC12019X07)；上海市卫生健康委先进适宜技术推广项目(2019SY071)；四川省科技厅重点研发项目(2021YFS0036)；四川省人社厅留学人员回国科技活动项目择优资助(川人社函〔2020〕291号)；成都市科技局重点产业研发支撑计划(2021-YF05-00473-SN)；福建省自然科学基金面上项目(2020J01981)；福建省卫生教育联合攻关计划项目(2019-wj-25)；广东省自然科学基金面上项目(2022A1515012617，2022A1515012394)；深圳市科技计划项目(JCYJ20210324121413037)。


Expert consensus on immunomodulatory drugs for nasal inflammatory diseases (2023，Shenzhen)
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    鼻部炎症性疾病临床主要包括变应性鼻炎(AR)、非变应性鼻炎(NAR)和慢性鼻窦炎(CRS)，其发病机制尚未完全阐明，涉及遗传学、免疫调节、炎症介质、环境因素、微生物群状态等多方面，传统药物治疗后部分患者症状仍无法缓解或出现不必要的副作用，且容易反复发作或呈慢性持续状态，因其发病多与免疫失衡相关，免疫调节是一个有效的治疗方案。近年来，免疫调节剂的品种和应用越来越广泛，主要包括化学合成制剂、生物制剂、人和动物免疫系统的产物、中药及其制剂等。但免疫调节剂治疗鼻部炎症疾病缺乏高水平的循证医学证据，使用尚不规范，因此，我们特组织该领域有经验的中青年鼻科专家，基于临床经验和循证医学证据制定了免疫调节剂治疗鼻部炎症性疾病专家共识，本共识从鼻部炎症性疾病发病机制角度出发，系统总结了鼻炎及CRS常用免疫调节剂的免疫作用机制、临床研究证据、适应证、用法用量及注意事项等，以供临床医生在选择和应用免疫调节剂时参考。

    Abstract:

    The clinical entity of nasal inflammatory diseases mainly includes allergic rhinitis, non-allergic rhinitis and chronic rhinosinusitis. The pathogenesis has not been fully clarified, involving genetics, immune regulation, inflammatory mediators, environmental factors, microbial community status, and other aspects. Conventional drug treatment may fail to relieve symptoms or even cause side effect in some patients.And the patients are prone to recurrent the disease or be in chronic persistent state. Considering its pathogenesis mostly related to immune imbalance, immune regulation is an effective treatment plan. Recently, the variety and application of immunomodulatory drugs have become more and more extensive, including chemically synthesized molecules, biological agents, products of human and animal immune systems, and traditional Chinese medicine. However, the application of immunomodulatory drugs in the treatment of nasal inflammatory diseases is not standardized due to the lack of high-level evidence-based medical evidences. Therefore, we intentionally organized young and middle-aged nasal experts with experience in this field to develop an expert consensus on immunomodulatory drugs for the treatment of nasal inflammatory diseases based on clinical experience and evidence-based medical evidence. This consensus systematically summarizes the immune mechanisms,clinical research evidence， indications, usage and dosage, as well as precautions of immunomodulatory drugs for rhinitis and chronic rhinosinusitis, so as to provide a reference for clinical selection and application of immunomodulatory drugs.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] 上海医学会儿科学分会免疫学组.儿童临床使用免疫调节剂(上海)专家共识[J].中华实用儿科临床杂志,2018,33(9):651-664.
    [2] Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: Allergic rhinitis[J]. Int Forum Allergy Rhinol,2018,8(2):108-352.
    [3] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.中国变应性鼻炎诊断和治疗指南(2022年, 修订版)[J].中华耳鼻咽喉头颈外科杂志,2022,57(2):106-129.
    [4] Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology[J].Allergy,2017，72(11):1657-1665.
    [5] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.中国慢性鼻窦炎诊断和治疗指南(2018)[J].中华耳鼻咽喉头颈外科杂志,2019,54(2):81-100.
    [6] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology,2020,58(Suppl S29):1-464.
    [7] Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021[J]. Int Forum Allergy Rhinol,2021,11(3):213-739.
    [8] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis[J]. Nat Rev Dis Primers, 2020,6(1):95.
    [9] Ponda P, Carr T, Rank MA, et al. Nonallergic rhinitis, allergic rhinitis, and immunotherapy: Advances in the last decade[J]. J Allergy Clin Immunol Pract, 2023,11(1):35-42.
    [10] Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper[J].Allergy, 2008,63(7):842-853.
    [11] Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities[J]. Allergy,2015,70(5): 533-539.
    [12] 王蠡,王成硕,娄鸿飞,等.维生素D与慢性鼻窦炎鼻息肉的研究进展[J].中国耳鼻咽喉头颈外科,2021,28(3):192-196.
    [13] 王成硕,张罗.慢性鼻窦炎的治疗策略[J].临床耳鼻咽喉头颈外科杂志,2016,30(14):1175-1178.
    [14] Chen S, Zhou A, Emmanuel B, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis[J]. Curr Med Res Opin,2020,36(11):1897-1911.
    [15] van der Veen J, Seys SF, Timmermans M, et al. Reallife study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre[J]. Allergy, 2017,72(2):282-290.
    [16] Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis[J]. J Allergy Clin Immunol, 2015,136(6):1431-1440.
    [17] 张朝巍.皮质激素类药物治疗过敏性鼻炎的临床研究进展[J].天津药学,2017,29(3):57-59.
    [18] Belvisi MG. Regulation of inflammatory cell function by corticosteroids[J]. Proc Am Thorac Soc,2004,1(3):207-214.
    [19] Doulaptsi M, Wils T, Hellings PW, et al. Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis[J]. World Allergy Organ J,2021,14(9):100585.
    [20] Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update[J]. Ann Allergy Asthma Immunol,2017,119(6):489-511.e41.
    [21] 罗玉,古庆家.变应性鼻炎的治疗进展[J].实用医院临床杂志,2021,18(3):211-213.
    [22] Okubo K, Kurono Y, Ichimura K, et al. Japanese guidelines for allergic rhinitis 2020[J]. Allergol Int, 2020, 69(3): 331-345.
    [23] Segboer C, Gevorgyan A, Avdeeva K, et al. Intranasal corticosteroids for non-allergic rhinitis[J]. Cochrane Database Syst Rev,2019,2019(11):CD010592.
    [24] Karatzanis A, Chatzidakis A, Milioni A, et al. Contemporary use of corticosteroids in rhinology[J]. Curr Allergy Asthma Rep,2017,17(2):11.
    [25] Bensch GW. Safety of intranasal corticosteroids[J]. Ann Allergy Asthma Immunol, 2016,117(6):601-605.
    [26] Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007)[J]. Clin Exp Allergy,2017,47(7):856-889.
    [27] Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression[J]. J Steroid Biochem Mol Biol,2014,144 Pt A:5-11.
    [28] Vanherwegen AS, Gysemans C, Mathieu C. Regulation of immune function by vitamin D and its use in diseases of immunity[J]. Endocrinol Metab Clin North Am, 2017,46(4):1061-1094.
    [29] Tian HQ, Cheng L. The role of vitamin D in allergic rhinitis. Asia Pac Allergy,2017,7(2):65-73.
    [30] Li B, Wang M, Zhou L, et al. Association between serum vitamin D and chronic rhinosinusitis: a meta-analysis[J]. Braz J Otorhinolaryngol,2021,87(2):178-187.
    [31] Ghaffari J, Ranjbar A, Quade A.Vitamin D deficiency and allergic rhinitis in children: a narrative review[J]. J Pediatr Rev, 2015,3(2):25-30.
    [32] Luo C, Sun Y, Zeng Z, et al. Vitamin D supplementation in pregnant women or infants for preventing allergic diseases: a systematic review and meta-analysis of randomized controlled trials[J]. Chin Med J (Engl),2022,135(3):276-284.
    [33] 周立立,江洪,蒋慧平,等.维生素D治疗变应性鼻炎疗效的Meta分析[J].医学综述,2019,25(9):1867-1873.
    [34] 陈斌,刘业海,里晓红,等.难治性变应性鼻炎患者血清维生素D水平及应用维生素D钙咀嚼片治疗的价值[J].临床耳鼻咽喉头颈外科杂志,2016,30(17):1397-1401.
    [35] Cho SW, Zhang YL, Ko YK, et al. Intranasal treatment with 1, 25-dihydroxyvitamin D3 alleviates allergic rhinitis symptoms in a mouse model[J]. Allergy Asthma Immunol Res,2019,11(2):267-279.
    [36] Hashemian F, Sadegh S, Jahanshahi J, et al. Effects of vitamin D supplementation on recurrence of nasal polyposis after endoscopic sinus surgery[J]. Iran J Otorhinolaryngol,2020,32(108):21-28.
    [37] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [J]. J Clin Endocrinol Metab,2011,96(7):1911-1930.
    [38] Pludowski P, Holick MF, Grant WB, et al. Vitamin D supplementation guidelines[J]. J Steroid Biochem Mol Biol,2018,175:125-135.
    [39] Płudowski P, Karczmarewicz E, Bayer M, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe -recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency[J]. Endokrynol Pol,2013,64(4):319-327.
    [40] Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol,2014,11(8):506-514.
    [41] Nermes M, Kantele JM, Atosuo TJ, et al. Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis[J]. Clin Exp Allergy,2011,41(3):370-377.
    [42] 许洋,赵宇,任健君,等.益生菌治疗变应性鼻炎的研究进展[J].临床耳鼻咽喉头颈外科杂志,2017,31(17):1322-1327.
    [43] Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic[J].Nat Rev Gastroenterol Hepatol,2019,16(10):605-616.
    [44] Luo C, Peng S, Li M,et al. The efficacy and safety of probiotics for allergic rhinitis: A systematic review and meta-analysis[J]. Front Immunol,2022,13:848279.
    [45] Güvenç IA, Muluk NB, Mutlu FŞ, et al. Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta-analysis[J]. Am J Rhinol Allergy,2016,30(5):157-175.
    [46] Colquitt AS, Miles EA, Calder PC. Do probiotics in pregnancy reduce allergies and asthma in infancy and childhood? A systematic review[J]. Nutrients, 2022,14(9):1852.
    [47] Giovannini M, Agostoni C, Riva E, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis[J]. Pediatr Res,2007,62(2):215-220.
    [48] 王智勇,苏丽娟,熊玉林,等.卡介菌多糖核酸在治疗儿童常年性变应性鼻炎的研究[J].检验医学与临床,2015,12(17):2523-2525.
    [49] 上海医学会儿科分会免疫学组.儿童临床使用免疫调节剂(上海)专家共识[J].中华实用儿科临床杂志，2018，33(9)：651-664.
    [50] 何金年,姚东方,李杰恩,等.卡介菌多糖核酸治疗变应性鼻炎的荟萃分析[J].中华临床免疫和变态反应杂志,2011,5(1):48-52.
    [51] Li J, Luo DF, Li SY, et al. Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study[J]. Chin Med J (Engl),2005,118(19):1595-1603.
    [52] De Benedetto F, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art[J]. Multidiscip Respir Med,2013,8(1):33.
    [53] Li C, Zhou H, Zhang W, et al. Bacterial lysate treatment in allergic disease: A systematic review and meta-analysis[J]. Pediatr Allergy Immunol, 2021,32(8):1813-1823.
    [54] Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa[J]. Rhinology, 2019,57(6):451-459.
    [55] Janeczek K, Emeryk A, Rachel M, et al. Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: A randomized controlled trial[J]. J Allergy Clin Immunol Pract, 2021,9(1):453-462.
    [56] Heintz B, Schlenter WW, Kirsten R,et al. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis--a multi-centric, placebo-controlled, double-blind study[J]. Int J Clin Pharmacol Ther Toxicol,1989,27(11):530-534.
    [57] Chen J, Zhou Y, Nie J, et al. Bacterial lysate for the prevention of chronic rhinosinusitis recurrence in children[J]. J Laryngol Otol,2017,131(6):523-528.
    [58] Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, et al. IgE-related chronic diseases and anti-IgE-based treatments[J]. J Immunol Res, 2016,2016:8163803.
    [59] Serrano-Candelas E, Martinez-Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils[J]. Clin Exp Allergy,2016,46(1):92-102.
    [60] Chang TW. The pharmacological basis of anti-IgE therapy[J]. Nat Biotechnol, 2000,18(2):157-162.
    [61] Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells[J]. Clin Transl Allergy, 2013,3(1):29.
    [62] Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma[J]. J Allergy Clin Immunol,2006,117(6):1493-1499.
    [63] Babu KS, Polosa R, Morjaria JB. Anti-IgE--emerging opportunities for Omalizumab[J]. Expert Opin Biol Ther,2013,13(5):765-777.
    [64] 陈玉迪,胡艳,隋海晶,等.抗IgE单克隆抗体在变态反应性疾病治疗中的应用[J].中华临床免疫和变态反应杂志,2018,12(3):302-307.
    [65] Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013,131(1):110-116. e1.
    [66] Bidder T, Sahota J, Rennie C,et al. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study[J]. Rhinology,2018,56(1):42-45.
    [67] Mostafa BE, Fadel M, Mohammed MA, et al. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis[J]. Eur Arch Otorhinolaryngol,2020,277(1):121-128.
    [68] Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials[J]. J Allergy Clin Immunol, 2020,146(3):595-605.
    [69] 中华医学会变态反应分会呼吸过敏学组(筹),中华医学会呼吸病学分会哮喘学组.中国过敏性哮喘诊治指南(第一版,2019年)[J].中华内科杂志,2019,58(9):636-655.
    [70] Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria[J]. Allergy, 2017,72(4):519-533.
    [71] Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study[J]. J Allergy Clin Immunol, 2022,149(3):957-965.e3.
    [72] Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study[J]. Respir Med,2017,130:55-60.
    [73] Oblitas CM, Galeano-Valle F, Vela-De La Cruz L, et al. Omalizumab as a provoking factor for venous thromboembolism[J]. Drug Target Insights, 2019,13:1177392819861987.
    [74] Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of Omalizumab in the treatment of allergic rhinitis: A systematic review and meta-analysis of randomized clinical trials[J]. Am J Rhinol Allergy, 2020,34(2):196-208.
    [75] Ma T, Wang H, Wang X. Effectiveness and response predictors of Omalizumab in treating patients with seasonal allergic rhinitis: A real-world study[J]. J Asthma Allergy,2021,14:59-66.
    [76] Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis[J].J Allergy Clin Immunol,2002,109:274-280.
    [77] Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children[J]. Allergy,2004,59(9):973-979.
    [78] Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis[J]. J Allergy Clin Immunol,2006,117(1):134-140.
    [79] Harb H, Chatila TA. Mechanisms of dupilumab[J]. Clin Exp Allergy, 2020,50(1):5-14.
    [80] Hoy SM. Dupilumab: A review in chronic rhinosinusitis with nasal polyps[J]. Drugs,2020,80(7):711-717.
    [81] 石帅,郑泉,程雷.度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展[J].山东大学耳鼻喉眼学报,2022,36(3):36-42.
    [82] Bachert C, Han JK, Desrosiers M, et al. Efcacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, doubleblind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet，2019，394(10209):1638-1650.
    [83] Kychygina A, Cassagne M, Tauber M, et al. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases[J]. Clin Rev Allergy Immunol，2022，62(3):519-533.
    [84] Busse WW, Maspero JF, Lu Y, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol,2020,125(5):565-576.e1.
    [85] Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma[J]. J Allergy Clin Immunol, 2018,142(1):171-177.e1.
    [86] Corren J, Saini SS, Gagnon R, et al. Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: A randomized trial[J]. J Asthma Allergy,2021,14:1045-1063.
    [87] 毛丽超,宋燕青,李雪松,等.新药美泊利单抗的研究进展[J].实用药物与临床,2016,19(10):1306-1309.
    [88] Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol,2020,145(3):725-739.
    [89] Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis[J]. J Allergy Clin Immunol, 2011,128(5):989-995.e1-8.
    [90] Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial[J]. J Allergy Clin Immunol,2017,140(4):1024-1031. e14.
    [91] Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count [J]. J Allergy Clin Immunol,2022,149(5):1711-1721.e6.
    [92] Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma[J]. Biologics,2013,7:7-11.
    [93] Weinstein SF, Katial RK, Bardin P, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol Pract, 2019,7(2):589-596.e3.
    [94] Markham A. Reslizumab: First global approval [J]. Drugs,2016,76(8):907-911.
    [95] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol,2006,118(5):1133-1141.
    [96] Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma[J]. Expert Opin Biol Ther,2012,12(1):113-118.
    [97] Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: A new approach for the treatment of severe eosinophilic asthma[J]. J Invest Allergol Clin Immunol, 2019,29(2):84-93.
    [98] Markham A. Benralizumab: First Global Approval[J]. Drugs，2018，78(4):505-511.
    [99] Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis[J]. Allergy， 2022，77(1):150-161.
    [100] Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis[J]. Respir Med， 2020，171:106080.
    [101] Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial[J]. J Allergy Clin Immunol， 2022，149(4):1309-1317.e12.
    [102] Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial[J]. Clin Exp Allergy，2021，51(6):836-844.
    [103] 马婷婷,刘士辉,石海云,等.脾氨肽口服溶液治疗季节性过敏性鼻炎的临床研究[J].中国耳鼻咽喉头颈外科,2022,29(9):596-599.
    [104] 冯波,张伟炜,郑启，等.脾氨肽口服液治疗变应性鼻炎的疗效及对T淋巴细胞亚群免疫平衡的影响[J].中华全科医学,2021,19(12):2038-2040，2044.
    [105] 龙镇,谢民强,田道法,蒋立新,等.加味补中益气汤治疗小鼠变应性鼻炎的实验研究[J].广东医学,2011,32(13):1661-1663.
    [106] 陈奔源. 基于NF-κB信号通路探讨玉屏风散口服液对变应性鼻炎小鼠IL-4和IFN-γ的影响[D].荆州：长江大学,2021.
    [107] 王金凤,王枫,赵桂芝,等.小青龙汤对过敏性鼻炎大鼠Th1/Th2细胞因子失衡及SP、Annexin1、VCAM-1表达的影响[J].现代中西医结合杂志,2022,31(15):2051-2057.
    [108] 龚美萍,陈思文,向红,等.补中益气汤治疗变应性鼻炎的Meta分析[J].中国民族民间医药,2021,30(11):77-80.
    [109] 潘虹.小青龙汤治疗变应性鼻炎临床观察[J].中医药临床杂志,2018,30(7):1326-1328.
    [110] 汪李琴,杨晴,程雷.中药玉屏风颗粒治疗变应性鼻炎的Meta分析[J].中国中西医结合耳鼻咽喉科杂志,2018,26(3):223-230.
    [111] Feleszko W, Rossi GA, Krenke R, et al.Immunoactive preparations and regulatory responses in the respiratory tract:potential for clinical application in chronic inflammatory airway diseases[J].Expert Rev Respir Med，2020，14(6):603-619.
    引证文献
引用本文

杨贵,廖芸,张维天,余少卿,杨钦泰,王向东,陈建军,孟娟,孟粹达,许元腾,孙悦奇,许成利,王英,杨玉成,刘锋,孙娜,赵可庆,唐隽,杨艳莉,陆美萍,邱前辉,王洪田,喻国冻,安云芳,左可军,石照辉,叶惠平,孙斌,孙亚男,曾明,许昱,巴罗,张天虹,顾瑜蓉,王天生,叶菁,谢志海,洪海裕,魏欣,徐睿,李勇,李华斌.免疫调节剂治疗鼻部炎症性疾病专家共识(2023，深圳)[J].中国耳鼻咽喉颅底外科杂志,2023,29(1):1-14

复制
分享
文章指标
  • 点击次数:2102
  • 下载次数: 1572
历史
  • 收稿日期:2023-01-18
  • 在线发布日期: 2023-03-03

中国耳鼻咽喉颅底外科杂志 ® 2025 版权所有 技术支持：北京勤云科技发展有限公司

温馨提示

本刊唯一投稿网址：www.xyosbs.com
唯一办公邮箱：xyent@126.com
编辑部联系电话：0731-84327210，84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系，谨防上当受骗！

关闭